Melatonin and Elevated ALT (SGPT): Causality and Management
Melatonin does not cause liver enzyme elevations in humans and, based on animal research, may actually protect against hepatotoxic injury; your elevated ALT is almost certainly unrelated to melatonin use and warrants investigation for other causes. 1, 2
Evidence Against Melatonin as a Hepatotoxin
Human Safety Data
In systematic reviews of randomized controlled trials involving 3,861 adults taking melatonin at doses ranging from 0.15 mg to 12 mg daily (monitored up to 29 weeks), elevated liver enzymes were not reported as an adverse event. 2
The most frequently documented adverse effects in clinical trials were daytime sleepiness (1.66%), headache (0.74%), dizziness (0.74%), and hypothermia (0.62)—with no mention of hepatotoxicity or transaminase elevations. 1, 2
Even at high doses (≥10 mg daily), meta-analysis of 79 studies showed melatonin increased only minor adverse events like drowsiness, headache, and dizziness (Rate Ratio 1.40), but did not cause serious adverse events or treatment withdrawals due to adverse effects. 3
Animal Research Shows Hepatoprotective Effects
In rat models of chemical liver injury (carbon tetrachloride and alpha-naphthylisothiocyanate), melatonin administration reduced serum ALT and AST levels rather than elevating them, demonstrating antioxidant and anti-inflammatory hepatoprotective properties. 4, 5
Melatonin post-treatment in CCl₄-induced liver damage prevented increases in ALT, AST, and γ-GT while improving liver histopathology and reducing oxidative stress markers. 4
In chronic sleep deprivation models (which themselves elevate liver enzymes), melatonin supplementation reversed the elevation of ALT (P<0.05) and AST (P<0.001) caused by sleep loss. 6
What You Should Do
Immediate Actions
Discontinue melatonin temporarily (1–2 weeks) and recheck ALT to establish temporal relationship; if ALT normalizes, melatonin was likely coincidental rather than causative. 1
Investigate alternative causes of elevated ALT systematically:
- Alcohol consumption (even moderate amounts)
- Metabolic syndrome components (obesity, insulin resistance, dyslipidemia)
- Viral hepatitis (hepatitis B and C serology)
- Autoimmune hepatitis (ANA, anti-smooth muscle antibody)
- Medications and supplements (acetaminophen, NSAIDs, statins, herbal products)
- Non-alcoholic fatty liver disease (most common cause in developed countries)
- Hemochromatosis (ferritin, transferrin saturation) 1
If Melatonin Continuation Is Desired
Given the overwhelming evidence that melatonin does not cause hepatotoxicity and may be hepatoprotective, you can safely resume melatonin at the recommended dose of 3 mg taken 1.5–2 hours before bedtime while pursuing workup for the true cause of ALT elevation. 1
Choose a United States Pharmacopeial Convention (USP) Verified formulation to ensure product purity and accurate dosing, as melatonin is regulated as a dietary supplement with variable quality control. 1
Important Caveats
Product Quality Concerns
- Because melatonin is regulated as a dietary supplement in the United States, contamination or mislabeling could theoretically introduce hepatotoxic substances; selecting USP-verified products minimizes this risk. 1
Duration Considerations
The American Academy of Sleep Medicine recommends limiting melatonin use for chronic insomnia to 3–4 months maximum due to insufficient long-term safety data beyond this period, though available evidence through 29 weeks shows favorable safety profiles. 1, 2
For circadian rhythm disorders (delayed sleep-wake phase disorder, non-24-hour sleep-wake rhythm disorder), longer-term melatonin therapy may be appropriate as these conditions require ongoing chronobiotic treatment. 1
When to Seek Urgent Evaluation
If ALT elevation is accompanied by jaundice, right upper quadrant pain, dark urine, pale stools, or constitutional symptoms (fever, weight loss), pursue urgent hepatology evaluation regardless of melatonin use. 1
Persistently elevated ALT (>2× upper limit of normal) warrants comprehensive hepatology workup including imaging (ultrasound or MRI) to exclude structural liver disease, even if melatonin is discontinued. 1